In December of last year, Roche acquired US private clinical-stage biotechnology company Carmot Therapeutics for $2.7 billion in cash. It was through this acquisition that Roche acquired CT-388, a clinical-stage asset to join the diet drug market dominated by Novo Nordisk (NVO.US) and LLY.US (LLY.US). Other pharmaceutical companies developing diet pills include Amgen (AMGN.US), Pfizer (PFE.US), and AstraZeneca (AZN.US).
罗氏(RHHBY.US)减肥药早期临床试验取得积极结果：24周后平均减重18.8%
Early clinical trials of Roche (RHHBY.US) diet pills achieved positive results: average weight loss of 18.8% after 24 weeks
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.